IBM

IBM

$224.44

+0.25%
Nov 20, 2026
Bobby Quantitative Model
International Business Machines Corporation (IBM) is a 115-year-old enterprise technology provider that delivers software (Red Hat, watsonx, automation, and data platforms), IT consulting and systems integration services, and infrastructure hardware including mainframes and quantum computing systems, operating across 175 countries and serving 95% of the Fortune 500. IBM's competitive identity is that of a legacy incumbent turned hybrid-cloud and enterprise-AI platform company — no longer a growth disruptor, but a sticky, high-switching-cost vendor whose value proposition rests on mission-critical workloads in finance, retail, and government rather than consumer-facing innovation. The current investor narrative is a tug-of-war between genuine operating momentum and AI-spending skepticism: Q3 2026 results showed software strength, mainframe resilience, and robust free cash flow, yet the stock sold off sharply after management flagged that enterprise clients are questioning AI spending without clear returns, and the shares have since fallen roughly 22% over the trailing year. That debate — whether IBM's AI and Red Hat-led software mix can compound through a cautious IT budget environment, or whether consulting cyclicality and AI digestion will cap growth — is the central question driving positioning in the name today.

People also watch

Accenture

Accenture

ACN

Analysis
Cognizant Technology Solutions

Cognizant Technology Solutions

CTSH

Analysis
Fiserv

Fiserv

FISV

Analysis
Broadridge Financial Solutions

Broadridge Financial Solutions

BR

Analysis
Fidelity National Information Services

Fidelity National Information Services

FIS

Analysis

BobbyInvestment Opinion: Should I buy IBM Today?

Rating: Hold with a constructive bias. The core thesis is that IBM's 22.4% one-year decline and 35% trailing-to-forward PE compression (26.07x to 16.91x on consensus EPS of $12.85) have de-rated a cash-generative franchise to a level where the risk/reward is balanced rather than compelling, anchored by a 12 Buy / 11 Hold / 2 Sell consensus (mean 2.28) and a $259.85 average target implying 16.1% upside from $223.88. The stock is not broken fundamentally — it is broken technically, and the two have not yet reconciled.

Supporting evidence is real but not overwhelming: trailing free cash flow of $14.34 billion covers the 2.27% dividend at a 59.0% payout ratio, Q3 2026 revenue of $17.103 billion grew 4.73% year-over-year with Software at $7.804 billion the largest segment, and operating margin expanded sequentially from 13.94% in Q1 to 15.24% in Q2 to 16.84% in Q3. Against that, gross margin slipped from 57.73% to 56.80% quarter-over-quarter, debt-to-equity is 2.06x with a current ratio of just 0.93, and the 4.09x PS and 8.46x P/B are premium multiples for a services-heavy business. The 16.1% gap to the average target is meaningful but sits inside a $174–$300 range — a 72% spread that signals the consensus is about multiple, not earnings, since EPS estimates cluster tightly at $12.56–$13.07.

The biggest risks that would invalidate this view are a consulting-led revenue miss, continued enterprise AI-budget digestion following the CEO's warning that clients question AI spending without clear returns, and a break below the $199.19 52-week low that triggers systematic selling. This Hold would upgrade to Buy on evidence of software growth re-accelerating above mid-single digits with operating margin recovering toward the 24.6% posted in Q4 2025, or on a pullback toward $199–$205 that widens the gap to the $259.85 target beyond 25%; it would downgrade to Sell if Q4 software growth decelerates below mid-single digits or if the dividend coverage comes into question given the 0.93 current ratio. On balance the stock is fairly valued to modestly undervalued relative to its own recent history but at a premium to IT services peers on sales and book — a fair price for a hybrid business, not a bargain.

Sign up to view all

IBM 12-Month Price Forecast

The forward-looking picture is balanced: IBM trades at 16.91x forward earnings for a business growing revenue at 4.73% with $14.34 billion of trailing free cash flow, which is neither cheap enough to be a deep-value call nor expensive enough to justify the 22.4% one-year decline on its own. The 16.1% gap to the $259.85 average target and the 12-11-2 Buy/Hold/Sell split suggest the market is waiting for evidence rather than repositioning, and the October 22 reiterations confirm that posture. The swing factor is software — if Red Hat and watsonx can compound fast enough to offset consulting cyclicality and push operating margin back toward the 24.6% Q4 2025 level, the de-rating looks overdone; if enterprise AI budgets stall, the 16.91x multiple is not the floor. I would upgrade to bullish on a reclaim of the $250–$258 resistance band accompanied by software growth above mid-single digits, and downgrade to bearish on a decisive break below $199.19 or a Q4 software deceleration below mid-single digits.

Historical Price
Current Price $224.44
Average Target $252.50
High Target $300.00
Low Target $174.00

Wall Street consensus

Most Wall Street analysts maintain a constructive view on IBM's 12-month outlook, with a consensus price target around $259.85 and implied upside of +15.8% versus the current price.

Average Target

$259.85

25 analysts

Implied Upside

+15.8%

vs. current price

Analyst Count

25

covering this stock

Price Range

$174 - $300

Analyst target range

Buy
12 (48%)
Hold
11 (44%)
Sell
2 (8%)

Coverage is broad and moderately constructive: 23 analysts cover IBM, with a distribution of 12 Buy, 11 Hold, and 2 Sell, yielding a consensus recommendation of "buy" (mean rating 2.28 on a scale where lower is more bullish). The average target price of $259.85 implies roughly 16.1% upside from the current $223.88, a meaningful but not euphoric gap that reflects the stock's recent de-rating rather than a uniform bullish call — the consensus leans cautiously bullish, with the Hold bloc nearly as large as the Buy bloc, signaling genuine two-sided debate. Notably, the most recent institutional actions (October 22, 2026) were almost entirely reiterations rather than upgrades or downgrades, suggesting analysts are waiting for evidence rather than repositioning aggressively.

The target range of $174.00 to $300.00 is wide — a 72% spread from low to high — which signals high uncertainty and low conviction in the out-year estimates. The high target of $300 assumes multiple expansion back toward the stock's prior highs, driven by accelerating software growth, successful AI monetization through watsonx and Red Hat, and mainframe-cycle resilience; the low target of $174 prices in consulting weakness, AI-spending digestion, margin compression, and a continued de-rating toward the 52-week low of $199.19 and below. Consensus EPS of $12.85 (range $12.56–$13.07) and revenue of $83.34 billion (range $81.91–$84.43 billion) are tightly clustered, meaning the disagreement is almost entirely about the multiple the market will pay rather than about the underlying business — a classic setup where sentiment, not fundamentals, is the swing factor, and where the wide target spread argues for disciplined entry rather than chasing.

Drowning in data?

Find the real signal!

Bulls vs Bears: IBM Investment Factors

The bear case currently has stronger near-term evidence: the stock is in a confirmed downtrend at 18.5% of its 52-week range, momentum deteriorated into November with a 9.4% four-day slide, and management itself flagged AI-spending caution that undermines the growth narrative. The bull case rests on valuation and cash flow rather than momentum — a 16.91x forward PE, $14.34 billion of trailing FCF, expanding operating margins, and a 16.1% gap to the average analyst target. The single most important tension is whether IBM's software segment can compound fast enough to offset consulting cyclicality and AI digestion; if software growth holds and margins keep expanding, the de-rating looks overdone, but if enterprise AI budgets stall, the 16.91x forward multiple is not the floor. With beta of 0.764, the severity of this decline is company-specific de-rating rather than market beta, which means the thesis, not the tape, must resolve the debate.

Bullish

  • Forward PE de-rated to 16.9x: The trailing PE of 26.07x compresses to a forward PE of 16.91x on consensus EPS of $12.85, a 35% compression that prices in meaningful earnings growth. For a company generating $14.34 billion in trailing free cash flow, a mid-teens forward multiple is undemanding relative to pure-play software peers.
  • Software-led revenue growth holding: Q3 2026 revenue of $17.103 billion grew 4.73% year-over-year, with Software at $7.804 billion the largest and highest-quality segment. Q1 2026 grew 9.5% over the prior year, showing the Red Hat and watsonx franchise can drive consolidated growth when consulting is not a drag.
  • Operating margin expanding through 2026: Operating margin climbed from 13.94% in Q1 2026 to 15.24% in Q2 and 16.84% in Q3, with net income rising from $1.216 billion to $2.189 billion over the same span. If software mix pushes margin back toward the 24.6% posted in Q4 2025, the forward EPS base has room to beat.
  • Analyst consensus buy with 16% upside: 23 analysts split 12 Buy, 11 Hold, 2 Sell for a mean rating of 2.28 and an average target of $259.85, implying 16.1% upside from $223.88. The high target of $300 implies 34% upside if software growth and AI monetization re-accelerate.

Bearish

  • Damaged chart, accelerating selloff: The stock is down 22.41% over one year and 23.20% YTD versus the S&P 500's +8.03%, a -30.44 percentage point relative-strength gap. It fell from $247.13 on November 13 to $223.88 by November 19, a 9.4% slide in four sessions, showing selling pressure is accelerating rather than stabilizing.
  • AI spending skepticism flagged by CEO: Management explicitly warned that enterprise clients are questioning AI spending without clear returns, and the stock sold off mid-call despite a Q3 earnings beat. That is a demand-side signal for the watsonx and consulting AI pipeline that consensus estimates of $83.34 billion revenue may not fully reflect.
  • Leveraged balance sheet, thin liquidity: Debt-to-equity is 2.06x, total debt-to-capitalization is 65.4%, and the current ratio is just 0.93. With $1.596 billion of dividends and $884 million of acquisitions in Q3 alone, the capital-return model leaves limited cushion if consulting or mainframe cycles disappoint.
  • Gross margin compressing on mix: Gross margin fell from 57.73% in Q2 2026 to 56.80% in Q3 and sits well below the 60.59% posted in Q4 2025, as lower-margin infrastructure and services take a larger share. ROA of just 5.33% confirms the underlying asset efficiency is modest despite a headline ROE of 32.45%.

IBM Technical Analysis

IBM is in a clear, sustained downtrend: the stock is down 22.41% over the trailing year and 23.20% year-to-date, a stark divergence from the S&P 500's +8.03% 1-year return, producing a relative-strength gap of -30.44 percentage points versus the index. At $223.88, the shares sit at roughly 18.5% of the 52-week range of $199.19–$332.46, meaning they are trading in the bottom fifth of their annual band — a positioning that signals persistent distribution and momentum breakdown rather than a healthy pullback, though it also places the stock closer to potential value-support than to overextension. The 37.5% maximum drawdown confirms this is a damaged chart, and the burden of proof now sits with buyers to establish a base.

Short-term momentum is negative and, importantly, deteriorating rather than stabilizing: the stock is down 7.46% over the past month and 5.01% over three months, with the 1-month decline outpacing the 3-month decline, indicating the selling pressure has actually accelerated into November. This is a bearish divergence from an already weak longer-term trend — the 1-month relative strength versus SPY is -0.54, so IBM is underperforming even a soft tape (SPY -6.92% over the same month), while the 3-month relative strength of +1.50 shows the stock had briefly held up better than the market earlier in the fall before rolling over again. The most recent sessions are the tell: the stock fell from $247.13 on November 13 to $223.88 by November 19, a roughly 9.4% slide in four trading days on volume of 3.77 million shares, a sharp, high-conviction breakdown that argues against calling a bottom prematurely.

Key technical levels are now well defined: the 52-week low of $199.19 is the critical support shelf, roughly 11% below the current $223.88 price, and a decisive break below it would confirm a fresh leg lower and likely trigger further systematic selling. Resistance sits at the 52-week high of $332.46, but the more actionable near-term resistance is the $250–$258 zone where the stock repeatedly failed in October and early November; reclaiming that band would be the first evidence of a trend repair. Volatility context matters here: IBM's beta of 0.764 means it is roughly 24% less volatile than the market, so the magnitude of this decline is unusually severe for a low-beta name and reflects company-specific de-rating rather than broad market beta — a distinction that matters for position sizing, since the risk is idiosyncratic and thesis-dependent rather than simply directional market exposure.

Beta

0.76

0.76x market volatility

Max Drawdown

-37.5%

Largest decline past year

52-Week Range

$199-$332

Price range past year

Annual Return

-22.7%

Cumulative gain past year

PeriodIBM ReturnS&P 500
1m-10.7%-9.7%
3m-4.8%-9.9%
6m-11.6%-7.5%
1y-22.7%+4.7%
ytd-23.0%+1.2%

Bobby - Your AI Investment Partner

Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions

IBM Fundamental Analysis

Revenue is growing but at a modest, decelerating-feeling pace: Q3 2026 revenue came in at $17.103 billion, up 4.73% year-over-year from $16.331 billion in Q3 2025, and the multi-quarter trajectory shows a company grinding out mid-single-digit growth rather than accelerating — Q2 2026 revenue of $17.162 billion was actually up only 1.1% versus Q2 2025's $16.977 billion, while Q1 2026's $15.917 billion grew 9.5% over Q1 2025's $14.541 billion. The segment mix explains the story: Software at $7.804 billion is the largest and highest-quality revenue line, Consulting at $5.335 billion is the cyclical drag tied to discretionary IT budgets, Infrastructure Services at $3.707 billion carries mainframe-cycle timing risk, and Financing at $192 million is immaterial. The implication for the investment case is that IBM's growth is real but software-dependent and lumpy, and any consulting softness or mainframe-cycle air pocket can quickly flatten the consolidated top line — which is precisely the risk the market is pricing.

IBM is solidly profitable, with Q3 2026 net income of $2.189 billion on a 12.80% net margin and a 56.80% gross margin, and the profitability trend is improving through the year: net income rose from $1.216 billion in Q1 2026 to $2.165 billion in Q2 and $2.189 billion in Q3, while operating margin expanded from 13.94% in Q1 to 15.24% in Q2 and 16.84% in Q3. Gross margin, however, has compressed modestly from 57.73% in Q2 to 56.80% in Q3 and sits below the 60.59% posted in Q4 2025, suggesting mix shift toward lower-margin infrastructure and services is a mild headwind. Against the broader IT services industry, a ~57% gross margin and high-teens operating margin are respectable but not exceptional — this is a scale-and-mix business, not a high-margin software pure-play — and the key watch item is whether software's mix contribution can push operating margin back toward the 24.6% level seen in Q4 2025.

The balance sheet is the real story and the real risk: debt-to-equity stands at 2.06x, the current ratio is a thin 0.93, and total debt-to-capitalization is 65.4%, reflecting a leveraged, capital-return-heavy model rather than a fortress balance sheet. Cash generation remains the anchor — trailing-twelve-month free cash flow is $14.343 billion, Q3 2026 FCF was $3.539 billion on $4.025 billion of operating cash flow, and the company returned capital aggressively with $1.596 billion of dividends and $352 million of buybacks in the quarter while also deploying $884 million on acquisitions. ROE of 32.45% looks impressive but is flattered by the leverage (equity multiplier above 4x), while ROA of just 5.33% reveals the underlying asset efficiency is modest; the dividend yield of 2.27% with a 59.0% payout ratio is well covered by FCF, but the combination of high debt, thin liquidity, and a heavy dividend commitment leaves limited cushion if consulting revenue or mainframe cycles disappoint.

Quarterly Revenue

$17.1B

2026-09

Revenue YoY Growth

+4.7%

YoY Comparison

Gross Margin

56.8%

Latest Quarter

Free Cash Flow

$14.3B

Last 12 Months

Revenue & Net Income Trends (2 Years)

Revenue Breakdown

Consulting
Financing
Infrastructure Services
Software
Segment Reconciling Items

Open an Account, get $2 TSLA now!

Valuation Analysis: Is IBM Overvalued?

Because IBM is profitable (Q3 2026 net income of $2.189 billion), the PE ratio is the appropriate primary metric, and the picture is more nuanced than the headline suggests: the trailing PE is 26.07x while the forward PE is 16.91x, a 35% compression that implies the market expects meaningful earnings growth — consistent with consensus EPS of $12.85 versus the current trailing EPS base. That wide trailing-to-forward gap is the crux of the valuation debate: investors are being asked to pay a mid-teens multiple on forward earnings for a low-single-digit revenue grower, which only works if margin expansion and software mix deliver. The PEG ratio of 0.35 is optically cheap, but it is distorted by the depressed trailing earnings base and should not be taken at face value.

Against the Information Technology Services industry, IBM screens as a premium asset on some measures and a discount on others: the PS ratio of 4.09x and EV/Sales of 3.90x are elevated for a services-heavy business, while the forward PE of 16.91x is reasonable relative to high-growth software peers and the EV/EBITDA of 19.07x sits in the middle of the range. The 8.46x price-to-book is rich, but that is a function of the leveraged capital structure rather than operational excellence. On balance, IBM trades at a modest premium to a typical IT services multiple on sales and book, but at a discount to pure-play software — a fair reflection of a hybrid business whose software segment deserves a higher multiple and whose consulting segment deserves a lower one.

Historically, IBM's own valuation band has been wide: the quarterly PE ratio ranged from 12.38x in Q4 2025 to 46.61x in Q1 2026, and the PS ratio ranged from 8.61x in Q4 2023 to 16.14x in Q3 2025, so the current 26.07x trailing PE and 4.09x PS (on the current market-cap basis) sit in the middle-to-lower portion of the recent historical range. The stock is not priced for perfection — the 22% one-year decline has de-rated it — but neither is it at a trough multiple that would signal a deep-value opportunity. The market appears to be pricing a modestly optimistic scenario: stable software growth, no consulting collapse, and gradual margin improvement, with limited margin of safety if any of those assumptions slip.

PE

26.1x

Latest Quarter

vs. Historical

Mid-Range

5-Year PE Range 11x~47x

vs. Industry Avg

19.1x

Industry PE ~19.1x*

EV/EBITDA

19.1x

Enterprise Value Multiple

Investment Risk Disclosure

Financial and operational risks center on a leveraged, capital-return-heavy model with limited slack. Debt-to-equity of 2.06x and total debt-to-capitalization of 65.4% sit alongside a current ratio of just 0.93, meaning short-term obligations nearly match liquid assets. Q3 2026 consumed $1.596 billion for dividends and $352 million for buybacks while also spending $884 million on acquisitions, so free cash flow of $3.539 billion in the quarter is doing a lot of work; a consulting air pocket or mainframe-cycle delay would pressure both the dividend coverage (59.0% payout) and the buyback. Revenue concentration in Software ($7.804 billion of $17.103 billion) means the growth thesis hinges on one segment, while gross margin already slipped from 57.73% in Q2 to 56.80% in Q3 as lower-margin infrastructure and services mix in.

Market and competitive risks are dominated by multiple compression and AI-spending digestion. At a trailing PE of 26.07x and PS of 4.09x, IBM trades at a premium to a typical IT services multiple on sales and book (8.46x P/B), so any further de-rating has room to run; the quarterly PE band has ranged from 12.38x to 46.61x, showing how violently sentiment can reprice this name. The CEO's warning that clients question AI spending without clear returns is a direct threat to the watsonx and consulting pipeline, and competitors like Oracle guiding to $225 billion in fiscal 2030 revenue and Arista posting higher-margin AI growth highlight IBM's slower, services-heavy profile. Beta of 0.764 limits broad-market correlation, but that also means the -22.41% one-year decline is idiosyncratic — the risk is thesis-specific, not simply directional exposure.

The worst-case scenario is a consulting-led revenue miss combined with continued AI-budget digestion, which would force analysts toward the $174 low target and a retest of the $199.19 52-week low. From $223.88, that is roughly -11% to the 52-week low and about -22% to the $174 bear target, while the 37.5% maximum drawdown shows how far a full de-rating can extend if the multiple compresses toward the 12.38x trough seen in Q4 2025. The chain would likely start with a Q4 software growth deceleration below mid-single digits, followed by margin guidance cuts and a dividend-coverage scare given the 0.93 current ratio, triggering systematic selling below $199.19. In that path, an investor could realistically lose 20-35% from current levels before value support emerges.

FAQ

Ranked by severity, the first risk is company-specific demand: the CEO's warning that enterprise clients question AI spending without clear returns directly threatens the watsonx and consulting pipeline, and the stock sold off mid-call despite a Q3 earnings beat — a signal that consensus revenue of $83.34 billion may not fully reflect budget digestion. Second is financial leverage and liquidity: debt-to-equity of 2.06x, total debt-to-capitalization of 65.4%, and a current ratio of just 0.93 leave thin cushion while Q3 alone consumed $1.596 billion for dividends and $352 million for buybacks alongside $884 million of acquisitions. Third is margin and mix risk: gross margin slipped from 57.73% in Q2 to 56.80% in Q3 and sits well below the 60.59% posted in Q4 2025 as lower-margin infrastructure and services take share, and ROA of just 5.33% confirms modest underlying asset efficiency despite a leverage-flattered 32.45% ROE. Fourth is valuation and competitive risk: at 4.09x PS and 8.46x P/B the stock has room to de-rate further, and competitors like Oracle guiding to $225 billion in fiscal 2030 revenue and Arista posting higher-margin AI growth highlight IBM's slower, services-heavy profile — with beta of 0.764 meaning the -22.41% one-year decline is idiosyncratic de-rating rather than market exposure.

The 12-month scenario set is weighted toward stabilization: a 55% base case targets $240–$265 (centered on the $259.85 analyst average, a 16.1% gain from $223.88) assuming revenue growth holds near 4.73%, operating margin stays in the 16–18% band, and the forward PE holds near 16.91x on $12.85 consensus EPS. A 25% bear case targets $174–$199, aligned with the analyst low target and the $199.19 52-week low, if consulting weakness and AI-budget digestion force the multiple toward the 12.38x trough seen in Q4 2025 — roughly -11% to -22% from current levels. A 20% bull case targets $280–$300, aligned with the $300 high target, if software re-accelerates on Red Hat and watsonx monetization and operating margin recovers toward the 24.6% posted in Q4 2025. The base case is most likely, and its key assumption is that the de-rating stops without a clear resolution of the AI-spending debate — the stock grinds toward target on cash flow support rather than on a re-rating catalyst.

The answer depends on which multiple you anchor to. On trailing earnings IBM looks expensive at 26.07x PE, but that compresses to 16.91x forward on consensus EPS of $12.85 — a 35% de-rating that already prices in meaningful earnings growth and is undemanding for a company generating $14.34 billion of trailing free cash flow. On sales and book the stock screens at a premium for a services-heavy business: 4.09x PS, 3.90x EV/Sales, and 8.46x P/B, with the book multiple inflated by a leveraged capital structure (2.06x debt-to-equity) rather than operational excellence, while EV/EBITDA of 19.07x sits mid-range. Against its own history the current multiples sit in the middle-to-lower portion of a wide band — quarterly PE has ranged from 12.38x in Q4 2025 to 46.61x in Q1 2026 — so the stock is neither priced for perfection nor at a trough that would signal deep value. The market appears to be paying a fair price for a hybrid business: a premium to IT services on sales and book, a discount to pure-play software, implying expectations of stable software growth, no consulting collapse, and gradual margin improvement with limited margin of safety if any assumption slips.

From a risk/reward standpoint IBM is balanced rather than compelling: at $223.88 it offers 16.1% upside to the $259.85 average analyst target, but that gap sits inside a $174–$300 range — a 72% spread that signals the consensus is about multiple, not earnings, since EPS estimates cluster tightly at $12.56–$13.07. The downside is well defined at roughly -11% to the $199.19 52-week low and about -22% to the $174 bear target, while the 16.91x forward PE on $12.85 consensus EPS and $14.34 billion of trailing free cash flow provide a valuation floor that pure momentum names lack. The biggest risk is that management itself flagged clients questioning AI spending without clear returns, a demand-side signal for the watsonx and consulting pipeline that could keep the multiple compressed. It is a reasonable buy for income-oriented, low-volatility investors (beta 0.764, 2.27% yield covered at a 59.0% payout) seeking a de-rated cash generator, and for value buyers willing to accumulate toward $199–$205 where the gap to target widens beyond 25%. It is not a good buy for growth investors who need evidence of accelerating software growth before committing capital.

IBM is structurally a long-term holding: revenue growing 4.73% year-over-year, a 2.27% dividend covered at a 59.0% payout by $14.34 billion of trailing free cash flow, and beta of 0.764 make it a low-volatility income-and-stability position rather than a trading vehicle. The near-term tape argues against short-term entry — the stock is down 7.46% over one month and 22.41% over one year, sits at 18.5% of its 52-week range, and fell 9.4% in four sessions from $247.13 to $223.88 — so momentum traders have no trend to ride and the chart remains damaged with a 37.5% maximum drawdown. Earnings visibility is moderate rather than high: consensus EPS clusters tightly at $12.56–$13.07, but the $174–$300 target spread shows analysts disagree on the multiple, not the business, and the Q4 software print is the swing factor. A concrete minimum holding period of 18–24 months is appropriate, allowing at least two Q4 software cycles to prove whether Red Hat and watsonx can offset consulting cyclicality and push operating margin back toward the 24.6% Q4 2025 level; shorter horizons should be limited to tactical accumulation near $199–$205 support.